Show simple item record

dc.contributor.authorRoesti, Elisa S
dc.contributor.authorBoyle, Christina N
dc.contributor.authorZeman, Daniel T
dc.contributor.authorSande-Melon, Marcos 
dc.contributor.authorStorni, Federico
dc.contributor.authorCabral-Miranda, Gustavo
dc.contributor.authorKnuth, Alexander
dc.contributor.authorLutz, Thomas A
dc.contributor.authorVogel, Monique
dc.contributor.authorBachmann, Martin F
dc.date.accessioned2020-03-25T07:25:28Z
dc.date.available2020-03-25T07:25:28Z
dc.date.issued2020-03
dc.identifier.citationVaccines (Basel). 2020; 8(1):116es_ES
dc.identifier.issn2076-393Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9321
dc.description.abstractType 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by insulin resistance and insufficient insulin secretion to maintain normoglycemia. The majority of T2DM patients bear amyloid deposits mainly composed of islet amyloid polypeptide (IAPP) in their pancreatic islets. These-originally β-cell secretory products-extracellular aggregates are cytotoxic for insulin-producing β-cells and are associated with β-cell loss and inflammation in T2DM advanced stages. Due to the absence of T2DM preventive medicaments and the presence of only symptomatic drugs acting towards increasing hormone secretion and action, we aimed at establishing a novel disease-modifying therapy targeting the cytotoxic IAPP deposits in order to prevent the development of T2DM. We generated a vaccine based on virus-like particles (VLPs), devoid of genomic material, coupled to IAPP peptides inducing specific antibodies against aggregated, but not monomeric IAPP. Using a mouse model of islet amyloidosis, we demonstrate in vivo that our vaccine induced a potent antibody response against aggregated, but not soluble IAPP, strikingly preventing IAPP depositions, delaying onset of hyperglycemia and the induction of the associated pro-inflammatory cytokine Interleukin 1β (IL-1β). We offer the first cost-effective and safe disease-modifying approach targeting islet dysfunction in T2DM, preventing pathogenic aggregates without disturbing physiological IAPP function.es_ES
dc.description.sponsorshipThese studies were funded by a project grant from the Swiss National Foundation (SNF). We acknowledge the technical assistance of Sydney W. Pence and Faith Slubowski at the Institute of Veterinary Physiology, University of Zürich. We appreciate the kind possibility given by Nanolive (Lausanne, Switzerland) for the opportunity and the collaborative acquisition of tomographic pictures.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectT2DMes_ES
dc.subjectAmyloides_ES
dc.subjectIslet amyloid polypeptidees_ES
dc.subjectVaccinees_ES
dc.subjectVirus-like particlees_ES
dc.titleVaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellituses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32131431es_ES
dc.format.volume8es_ES
dc.format.number1es_ES
dc.format.page116es_ES
dc.identifier.doi10.3390/vaccines8010116es_ES
dc.contributor.funderSwiss National Foundation
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/vaccines8010116es_ES
dc.identifier.journalVaccineses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Desarrollo del Epicardio y su Papel en la Regeneraciónes_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional